These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 28233020)

  • 1. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
    Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
    Chen FP; Fu TS; Lin YC; Lin YJ
    Osteoporos Int; 2021 Apr; 32(4):663-670. PubMed ID: 33113007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial.
    Murdoch R; Mellar A; Horne AM; Billington E; Chan PL; Gamble GD; Reid IR
    J Bone Miner Res; 2023 May; 38(5):631-638. PubMed ID: 36970850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
    Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
    Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
    Wark JD; Bensen W; Recknor C; Ryabitseva O; Chiodo J; Mesenbrink P; de Villiers TJ
    Osteoporos Int; 2012 Feb; 23(2):503-12. PubMed ID: 21331467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
    Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
    Black DM; Reid IR; Napoli N; Ewing SK; Shiraki M; Nakamura T; Takeuchi Y; Schafer AL; Kim TY; Cauley JA
    J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
    Makras P; Anastasilakis AD; Polyzos SA; Bisbinas I; Sakellariou GT; Papapoulos SE
    Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
    Kassi G; Papamichael K; Papaioannou G; Giagourta I; Thanou S; Triantaphyllopoulou M; Zapanti E; Papandroulaki F; Ktena V; Karga H
    Immunol Invest; 2014; 43(6):544-55. PubMed ID: 24661204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.